The global cardiopulmonary stress testing devices market size is expected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing incidence of cardiovascular and pulmonary disorders including arrhythmia and heart valve imbalance.
Cardiopulmonary stress testing is used to assess exercise ability and predict outcome in patients with heart failure. It is a non-invasive, highly adaptive stress examination that assesses the cardiovascular, pulmonary, neurophysiological, hematopoietic, and skeletal muscle systems' responses to exercise. Ischemic heart disease, heart failure, shortness of breath, asthma, and other lung diseases can also be detected with cardiopulmonary stress monitoring. The main aim of cardiac stress testing is to determine coronary artery disease (CAD) risk stratification, which is one of the leading causes of death worldwide. It's a disease that causes blood vessels in the arteries that supply blood to the heart muscles to get clogged.
The report on the global cardiopulmonary stress testing includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes | Details |
Report Title | Cardiopulmonary Stress Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | Application (Exercise Tolerance Testing Devices, Echocardiograph Testing Devices, Nuclear Stress Testing Devices), Product (Exercise Stress Testing Devices and Pharmacological Stress Testing Devices) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Thermo Fisher Scientific Ltd; Philips Healthcare; Care Medical Ltd; Cosmed Medical; Cardiac Science Corporation; GE Healthcare; TouchPoint; Cardinal Health; NIHON KOHDEN CORPORATION; Vyaire Medical Inc.; W.L. Gore & Associates |
The exercise tolerance testing devices segment is expected to account for a key share of the market
Based on application, the cardiopulmonary stress testing market is segmented into exercise tolerance testing devices, echocardiograph testing devices, nuclear stress testing devices. The exercise tolerance testing devices segment is expected to account for a key share of the market during the forecast period owing to the accuracy and the least operating by these devices. Also, exercise tolerance testing devices are cost effective and has multiple use is another factor that is expected to propel the market growth.
The pharmacological stress testing device segment is expected to constitute a key share of the market
Based on product, the cardiopulmonary stress testing market is bifurcated into Exercise Stress Testing Devices and Pharmacological Stress Testing Devices. The pharmacological stress testing device segment is expected to constitute a key share of the market during the forecast period due to the increasing geriatric population with decreased functional capacity.
North America is anticipated to dominate the market
On the basis of regions, the cardiopulmonary stress testing is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to increased awareness about the advantages of cardiopulmonary stress testing amongst medical professionals.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increased prevalence of cardiovascular and pulmonary diseases in the region. Worldwide, high levels of air pollution have resulted in an unprecedented rise in respiratory and cardiovascular diseases.
Key players competing in the cardiopulmonary stress testing market are Thermo Fisher Scientific Ltd; Philips Healthcare; Care Medical Ltd; Cosmed Medical; Cardiac Science Corporation; GE Healthcare; TouchPoint; Cardinal Health; NIHON KOHDEN CORPORATION; Vyaire Medical Inc.; W.L. Gore & Associates.
Few of the industry's key players in the market are aggressively acquiring other firms to strengthen their market positions across the world, while some are introducing new products. Vyaire Medical Inc, for example, received FDA approval in August 2019 for its two Novel Pulmonary Function Testing Products, Vyntus ONE and Vyntus BODY, which extended their current Vyntus product line, which runs on the SentrySuite Software. The approved products offer a new ergonomic design as well as reliable and effective respiratory monitoring. The companies in the cardiopulmonary stress testing market are facing moderate level of competition.
Key players competing in the cardiopulmonary stress testing market are Thermo Fisher Scientific Ltd; Philips Healthcare; Care Medical Ltd; Cosmed Medical; Cardiac Science Corporation; GE Healthcare; TouchPoint; Cardinal Health; NIHON KOHDEN CORPORATION; Vyaire Medical Inc.; W.L. Gore & Associates.
Few of the industry's key players in the market are aggressively acquiring other firms to strengthen their market positions across the world, while some are introducing new products. Vyaire Medical Inc, for example, received FDA approval in August 2019 for its two Novel Pulmonary Function Testing Products, Vyntus ONE and Vyntus BODY, which extended their current Vyntus product line, which runs on the SentrySuite Software. The approved products offer a new ergonomic design as well as reliable and effective respiratory monitoring. The companies in the cardiopulmonary stress testing market are facing moderate level of competition.
Some other reports from this category!